A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00067782
First received: August 27, 2003
Last updated: April 7, 2011
Last verified: January 2010

August 27, 2003
April 7, 2011
December 2002
March 2005   (final data collection date for primary outcome measure)
Time to virologic rebound for subjects with HIV RNA < 50 c/mL at baseline; Magnitude/ durability of increases from baseline in absolute CD4 (Time-Averaged Difference) through WK12; Mean % change from baseline in fasting LDL cholesterol at WK12.
Not Provided
Complete list of historical versions of study NCT00067782 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
Not Provided

The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Atazanavir (immediate switch)
    Capsules, Oral, 400mg, Once daily, 48 weeks.
    Other Name: Reyataz
  • Drug: Atazanavir (Week 24 switch)
    Capsules, Oral, 400mg, Once daily, 48 weeks.
    Other Name: Reyataz
  • Active Comparator: 1
    Intervention: Drug: Atazanavir (immediate switch)
  • Active Comparator: 2
    Intervention: Drug: Atazanavir (Week 24 switch)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
March 2005
March 2005   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Must be on current HIV treatment regimen at least 3 to 6 months prior to study (this must be one protease inhibitor, or ritonavir-boosted protease inhibitor, and two nucleoside reverse transcriptase inhibitors) must be subject's first PI ever received
  • Plasma HIV-1 RNA level < 50 c/mL within 3 to 6 months prior to study start
  • Fasting LDL cholesterol > 130 mg/dL

Key Exclusion Criteria:

  • WOCBP who do not use effective barrier contraception for any reason
  • Women who are pregnant or breast feeding
  • A life expectancy < 12 months
  • Presence of a newly diagnosed HIV-related OI or any medical condition requiring acute therapy at the time of enrollment
  • Cushing's Syndrome
  • Uncontrolled diabetes mellitus, history of diabetic ketoacidosis or hyperosmolar syndrome
  • Untreated hypothyroidism or hyperthyroidism
  • Nephrotic syndrome or significant proteinuria
  • Obstructive liver disease
  • Active alcohol or substance abuse
  • Proven or suspected acute hepatitis in the 30 days prior to study entry
  • Intractable diarrhea (greater than or equal to 6 loose stools/day for at least 7 consecutive days) within 30 days prior to study start
  • History of acute or chronic pancreatitis
  • Inability to swallow capsules
  • Presence of cardiomyopathy
  • Known history of prolonged QTc interval
  • Any of the following:

    1. clinical symptoms potentially related to heart block
    2. heart rate < 40 bpm
    3. any of the following EKG abnormalities:

    i) pause length > 3 seconds ii) second or third degree AV heart block iii) QTc interval > 450 msec for males iv) QTc interval > 470 msec for females

  • Fasting serum triglyceride level > 750 mg/dL
  • Any of the following lab values within 2 weeks of starting study drug:

    1. serum creatinine greater to or equal to 1.5 times the upper limit of normal
    2. total serum lipase greater than or equal to 1.4 times the upper limit of normal
    3. liver transaminases greater than or equal to 3 times the upper limit of normal
    4. total serum bilirubin greater than or equal to 1.5 times the upper limit of normal
  • Hypersensitivity to any component of the formulation of study drug
  • Use of any lipid-lowering agent within 4 weeks prior or during study
  • Use of a PI-containing ARV regimen prior to entry which is comprised of more than one PI
  • Inclusion of an NNRTI in the PI-containing regimen
  • Prisoners or subjects involuntary incarcerated for treatment of psychiatric or physical illness
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00067782
AI424-067
Not Provided
Not Provided
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP